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Abstract
Introduction: Rheumatoid arthritis is an inflammatory disease with high incidence of cardiovascular disease due to
accelerated atherosclerosis. Osteoprotegerin (OPG) has been associated with increased risk of atherosclerotic disease in the
general population. Several polymorphisms in the OPG gene with functional effects on cardiovascular disease in non-
rheumatic individuals have been described. Therefore, we aimed to analyze the effect of three of these functional OPG
polymorphisms on the risk of cardiovascular disease in a large and well-characterized cohort of Spanish patients with
rheumatoid arthritis.
Methods: Three OPG gene variants (rs3134063, rs2073618 and rs3134069) were genotyped by TaqMan assays in 2027
Spanish patients with rheumatoid arthritis. Anti-cyclic citrullinated peptide (anti-CCP) antibody testing was positive in 997 of
1714 tested. Also, 18.3% of the whole series had experienced cardiovascular events, including 5.4% with cerebrovascular
accidents. The relationship between OPG variants and cardiovascular events was assessed using Cox regression.
Results: No association between OPG gene variants and cardiovascular disease was observed in the whole group of
rheumatoid arthritis patients or in anti-CCP positive patients. Nevertheless, a protective effect of CGA haplotype on the risk
of cardiovascular disease in general, and specifically in the risk of cerebrovascular complications after adjusting for sex, age
at disease diagnosis and traditional cardiovascular risk factors was disclosed in anti-CCP negative patients (HR= 0.54; 95%CI:
0.31–0.95; p = 0.032 and HR= 0.17; 95%CI: 0.04–0.78; p = 0.022, respectively).
Conclusion: Our results indicate a protective effect of the OPG CGA haplotype on cardiovascular risk, mainly due to a
protective effect against cerebrovascular events in anti-CCP negative rheumatoid arthritis patients.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory rheumatic
disease associated with high incidence of cardiovascular (CV)
morbidity and mortality compared to the general population [1–
4], similarly to what occurs in type 2 diabetes [5,6]. Specifically, it
has been shown a high incidence of coronary heart disease and a
high rate of CV events in RA [7,8] due to accelerated
atherosclerosis [9]. Besides traditional CV risk factors [4,10] and
the magnitude and severity of the chronic inflammatory response
[8], genetic factors located inside [8] and outside the Human
Leukocyte Antigen (HLA) region [11,12] play a pivotal role in the
development of atherogenesis in RA [13–15].
Osteoprotegerin (OPG) belongs to the TNF receptor super-
family and is implicated in bone remodeling and in the
atherosclerotic process. This molecule acts as a decoy receptor
for the receptor activator of nuclear factor-kB ligand (RANKL),
inhibiting binding of RANKL to its receptor, RANK [16,17].
Binding of RANKL to OPG inhibits osteoclastogenesis, although
it is also well known that both molecules are involved in vascular
wall mineralization [16]. Additionally, OPG acts as a soluble
neutralizing receptor of TNF-related apoptosis-inducing ligand
(TRAIL), an anti-inflammatory molecule with anti-atherosclerotic
properties [18–20]. Despite having a paradoxically protective
effect on vascular calcification [21,22], OPG has been associated
with increased risk of atherosclerotic disease in the general
population [23].
The human OPG gene (also called TNFRSF11B) is located on
chromosome 8q24. This gene is affected by genetic polymor-
phisms with functional consequences on CV disease and bone
metabolism [24,25]. Recently, several groups have reported that a
single-nucleotide OPG polymorphism (SNP) located in the 59
UTR region (rs2073617), as well as one in exon 1 (rs2073618) and
another in the promoter region (rs3134069) were associated with
atherosclerosis and risk of cerebrovascular disease in non-
rheumatic individuals [26,27].
Considering the functional involvement of the above mentioned
OPG polymorphisms in the CV disease, in the present study we
aimed to analyze the potential association of these gene variations
on the risk of developing CV disease in a large and well-
characterized cohort of patients with RA, also evaluating their
combined effect on this risk.
Materials and Methods
Patients and Study Protocol
A set of 2027 Spanish patients with RA were included in the
present study. Blood samples were obtained from patients
recruited from Hospital Lucus Augusti (Lugo), Hospital Marque´s
de Valdecilla (Santander), Hospital de Bellvitge (Barcelona), and
Hospital Clı´nico San Carlos, Hospital La Paz, Hospital La
Princesa, Hospital Gregorio Maran˜o´n and Hospital 12 de Octubre
(Madrid). A subject’s written consent was obtained according to
the declaration of Helsinki, and the study was approved by the
Ethics Committee of Galicia for Hospital Lucus Augusti, of
Cantabria for Hospital Universitario Marque´s de Valdecilla, of
Catalun˜a for Hospital de Bellvitge and of Madrid for Hospital
Clı´nico San Carlos, Hospital La Paz, Hospital La Princesa,
Hospital Gregorio Maran˜o´n and Hospital 12 de Octubre. All the
patients fulfilled the 1987 American College of Rheumatology
(ACR) and also the 2010 classification criteria for RA [28,29]. In
all the cases, the samples were assessed for OPG rs2073618 and
rs3134069 polymorphisms. Additionally, rs2073617 polymor-
phism was assessed with a pre-designed Taqman probe for the
rs3134063 polymorphism, which is in complete linkage disequi-
librium with rs2073617 (r2 = 1, http://hapmap.ncbi.nlm.nih.gov/
). The linkage disequilibrium (LD) pattern of the OPG polymor-
phisms analyzed in our study obtained by HapMap Project phase
I, II and III (in the European population) and HAPLOVIEW
(v.4.2) software is displayed in Figure 1.
Information on the main demographic data, clinical character-
istics, CV risk factors and CV events of patients enrolled in the
study is shown in Table 1. Anti-cyclic citrullinated peptide (anti-
CCP) antibody testing were positive in 997 (58.2%) of 1714 RA
patients in whom this result was available. Three hundred and
seventy (18.3%) of these 2027 patients had experienced CV events.
One-hundred and nine (5.4%) of the 2027 patients had suffered
cerebrovascular accidents. Definitions of CV events and tradition-
al CV risk factors were established as previously described [8,30].
Genotyping
DNA from patients was obtained from peripheral blood using
standard methods. The OPG rs3134063, rs2073618 and
Figure 1. Linkage disequilibrium (LD) pattern of the OPG
polymorphisms analyzed in our study (in European popula-
tion). Data obtained by HapMap Project phase I, II and III and
HAPLOVIEW (v.4.2) software. The LD between the OPG polymorphisms
studied is shown in a scale from minimum (white) to maximum (black).
doi:10.1371/journal.pone.0106823.g001
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rs3134069 polymorphisms were genotyped with TaqMan SNP
pre-designed genotyping assays (C__32324439_10,
C___1971047_1_, and C__27464534_10, respectively) in a 7900
HT real-time polymerase chain reaction (PCR) system, according
to the conditions recommended by the manufacturer (Applied
Biosystem, Foster City, CA, USA). Negative controls and duplicate
samples were included to check the accuracy of genotyping.
Statistical analysis
The genotype data were checked for deviation from Hardy-
Weinberg equilibrium (HWE) using http://ihg.gsf.de/cgi-bin/
hw/hwa1.pl.
The relationship between alleles, genotypes and haplotypes, and
CV events that occurred in the follow-up was tested using Cox
regression adjusting for sex, age at RA diagnosis and traditional
CV risk factors. For that purpose, we used the most frequent allele,
genotype and haplotype as reference; the end of follow-up was the
first date among the end of the study, date of death or date of CV
event. Follow-up time was estimated as the difference between the
Table 1. Demographic and clinical characteristics of the Spanish patients with RA included in the study.
Clinical Feature % (n/N)
Patients 2027
Main characteristics Age at the time of disease onset (years, mean 6 SD) 51.2614.9
Follow-up (years, mean 6 SD) 11.768.4
Female gender 75.3 (1527/2027)
Rheumatoid factor positive* 68.6 (1344/1958)
Anti-CCP antibodies positive 58.2 (997/1714)
Shared epitope positive 63.7 (726/1139)
Cardiovascular risk factors Hypertension 38.2 (763/1996)
Diabetes mellitus 12.3 (246/1995)
Dyslipidemia 35.9 (713/1984)
Obesity 18.8 (345/1840)
Smoking habit 24.9 (491/1974)
Patients with cardiovascular events 18.3 (370/2027)
Ischemic heart disease 8.9 (180/2020)
Heart failure 5.6 (113/2027)
Cerebrovascular accident 5.4 (109/2027)
Peripheral arteriopathy 2.6 (52/2025)
CCP: cyclic citrullinated protein/peptide antibodies; RA: rheumatoid arthritis; SD: standard deviation.
*At least two determinations at different times were required.
doi:10.1371/journal.pone.0106823.t001
Table 2. Results of haplotype analysis in anti-CCP negative RA patients in association with CV events.
Variable HR (95% CI) p
Age at RA diagnosis
(by each year)
1.08 (1.06–1.10) ,0.001
Hypertension 0.98 (0.63–1.51) 0.929
Diabetes mellitus 1.58 (1.01–2.45) 0.043
Obesity 1.22 (0.78–1.89) 0.390
Dyslipidemia 1.27 (0.84–1.93) 0.254
Smoking 1.12 (0.85–1.48) 0.417
Haplotypes (rs3134063, rs2073618, rs3134069) HR (95% CI)* p*
TCA 1 (reference) -
TGA 0.94 (0.55–1.60) 0.825
CCA 1.09 (0.68–1.76) 0.724
CGA 0.54 (0.31–0.95) 0.032
CCP: cyclic citrullinated protein/peptide antibodies; CI: confidence interval; CV: cardiovascular; HR: hazard ratios; RA: rheumatoid arthritis.
*Adjusted for sex, age at RA diagnosis and traditional CV risk factors (hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking habit).
doi:10.1371/journal.pone.0106823.t002
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RA diagnosis date and the end of follow-up. Patients without CV
events in the follow-up time or dying by any non-CV cause were
considered as censored. Results were expressed as hazard ratios
(HR) with 95% confidence interval (CI). Statistical significance was
defined as p#0.05, and all analyses were performed using STATA
statistical software 12/SE (Stata Corp., College Station, TX,
USA).
Results
OPG rs3134063, rs2073618 and rs3134069 genotype distribu-
tion was in Hardy-Weinberg equilibrium (p.0.05). Genotyping
success was greater than 96% in all the cases. Genotype and allele
frequencies of the OPG rs3134063, rs2073618 and rs3134069
polymorphisms were in agreement with the data of the HapMap
project (http://hapmap.ncbi.nlm.nih.gov/).
There was no association between OPG gene variants and CV
disease when all the RA patients were assessed as a whole. It was
also the case for the group of anti-CCP positive patients (data not
shown). Nevertheless, an association between OPG gene poly-
morphisms and CV disease was observed in those who were anti-
CCP negative (Table 2). In this regard, even if no association was
observed between allelic and genotypic OPG variants and CV
disease (not shown), in the haplotype analysis, a protective effect of
Table 3. Association between OPG polymorphisms and the risk to develop cerebrovascular events in anti-CCP negative RA
patients.
SNP Genotype/Allele HR (95%CI) p*
rs3134063 TT 1 (reference) -
CT 0.61 (0.21–1.76) 0.362
CC 0.14 (0.02–1.23) 0.077
T 1 (reference) -
C 0.52 (0.26–1.06) 0.072
rs2073618 CC 1 (reference) -
CG 0.60 (0.20–1.82) 0.368
GG 0.17 (0.03–0.89) 0.035
C 1 (reference) -
G 0.45 (0.22–0.91) 0.025
rs3134069 AA 1 (reference) -
AC 1.20 (0.26–5.64) 0.814
CC - -
A 1 (reference) -
C 1.18 (0.27–5.09) 0.823
CCP: cyclic citrullinated protein/peptide antibodies; CI: confidence interval; HR: hazard ratios; RA: rheumatoid arthritis.
*Adjusted for sex, age at RA diagnosis and traditional CV risk factors (hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking habit).
doi:10.1371/journal.pone.0106823.t003
Table 4. Results of haplotype analysis in anti-CCP negative RA patients in association with cerebrovascular events.
Variable HR (95% CI) p
Age at RA diagnosis
(by each year)
1.09 (1.05–1.13) ,0.001
Hypertension 1.13 (0.51–2.48) 0.769
Diabetes mellitus 3.71 (1.78–7.70) ,0.001
Obesity 1.28 (0.58–2.83) 0.547
Dyslipidemia 0.80 (0.39–1.66) 0.556
Smoking 1.13 (0.68–1.88) 0.632
Haplotypes (rs3134063, rs2073618, rs3134069) HR (95% CI)* p*
TCA 1 (reference) -
TGA 1.38 (0.56–3.42) 0.487
CCA 1.16 (0.49–2.76) 0.740
CGA 0.17 (0.04–0.78) 0.022
CCP: cyclic citrullinated protein/peptide antibodies; CI: confidence interval; CV: cardiovascular; HR: hazard ratios; RA: rheumatoid arthritis.
*Adjusted for sex, age at RA diagnosis and traditional CV risk factors (hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking habit).
doi:10.1371/journal.pone.0106823.t004
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the CGA haplotype on the risk of CV disease after adjusting for
sex, age at RA diagnosis and traditional CV risk factors was
disclosed in the group of anti-CCP negative RA patients
(HR = 0.54; 95% CI: 0.31–0.95; p = 0.032) (Table 2).
In a further step, we aimed to determine the type of CV event
associated with OPG gene variants in the group of anti-CCP
negative patients. Whereas no association was observed with
ischemic heart disease (data not shown), we found an association of
cerebrovascular complications with rs2073618 OPG polymor-
phism in this group of patients. In this respect, the risk of
cerebrovascular complications was statistically decreased in the
group of anti-CCP negative patients who carried the OPG
rs2073618 GG genotype after adjusting the results for potential
confounder factors (HR = 0.17; 95% CI: 0.03–0.89; p = 0.035)
(Table 3). In accordance with these results, a protective effect of
the CGA haplotype on the risk of cerebrovascular events after
adjusting for sex, age at RA diagnosis and traditional CV risk
factors was observed in the anti-CCP negative RA patients
(HR = 0.17; 95% CI: 0.04–0.78; p = 0.022) (Table 4).
Discussion
RA is associated with increased morbidity and mortality
attributable to accelerated atherosclerosis and CV events [7,9],
in a similar fashion to what is observed in other autoimmune
diseases such as diabetes [6]. Therefore, the search of new genetic
markers which could help physicians to stratify RA patients
according to their CV risk, leading thus to an improved and more
personalized treatment, has become a main goal for several groups
of research.
OPG has been proposed as a potential biomarker of CV risk
since increased levels of this protein have been associated with CV
disease [23]. In this regard, OPG levels were associated with
biomarkers of endothelial activation (intercellular adhesion mol-
ecule-1), carotid intima-media wall thickness and carotid plaques
in RA patients with severe disease [31]. In keeping with these
results, an independent correlation of OPG levels with asymmetric
dimethylarginine (ADMA), another biomarker of endothelial cell
activation, has been disclosed in ankylosing spondylitis patients
undergoing anti-TNF-a therapy [32]. Increasing concentrations of
OPG have also been associated with the severity of CV
complications in diabetic patients [33–37], reinforcing the idea
that OPG could be used as a prognostic factor of CV disease in the
clinic.
Several groups have described sequence variations in the gene
that codifies OPG [24–26]. As elegantly proposed by Soufi et al.,
variations in the different regions of the OPG gene could combine
to affect its transcription, intracellular trafficking or secretion [24].
To the best of our knowledge, our study constitutes the first
attempt to assess the potential effect of rs3134063, rs2073618 and
rs3134069 on the risk to develop CV disease in a large and well-
characterized cohort of RA patients.
When we studied the influence of the different OPG polymor-
phisms on the risk of CV disease, we found a protective effect of
the CGA haplotype on the risk of CV events in the subgroup of
RA patients who were anti-CCP negative. Interestingly, further
analyses disclosed that this protective effect was specifically focused
on the risk of developing cerebrovascular accidents. In this regard,
anti-CCP negative RA patients who carried an OPG rs20730618
GG genotype had a lower risk of developing cerebrovascular
complications. Additionally, when we combined the different
genetic variants to create haplotypes, our results also revealed a
protective effect of the CGA haplotype (that carries the G allele of
the OPG rs2073618) against the risk of cerebrovascular events in
the subgroup of anti-CCP negative RA patients. These results are
in line with those obtained by Biscetti et al., who found a
synergistic effect of rs3134069, rs2073617 and rs2073618 associ-
ated with cerebral ischemic events in a cohort of diabetic patients
[27]. Likewise, our results are in accordance with those obtained
by Mankocˇ Ramusˇ et al., who also found an association between a
combination of two of the OPG gene variants studied by our group
and diabetic retinopathy [38].
Interestingly, the protective effect of the OPG CGA haplotype
was found in anti-CCP negative but not anti-CCP positive RA
patients. This could be explained by the fact that anti-CCP
positive and anti-CCP negative RA are considered different
disease entities [39]. Several pieces of evidence disclose that anti-
CCP antibodies are markers of severe disease, and that risk factors
such as HLA class II alleles associate with anti-CCP status and a
more severe disease course [40]. In this regard, anti-CCP positive
RA patients display a more severe radiological destruction and
elevated DAS28 and CRP values than anti-CCP negative patients
[39,41].
Taken all these considerations together, our results and those
previously mentioned support the idea that, in an attempt to
establish the potential association between multiple genetic
markers in a chromosomal region and traits of interest in complex
diseases, haplotype analyses appear to provide more useful
information than the separate assessment of individual gene
variants [27,38,42–45]. Hence, combination analyses often help to
disclose hidden signals and may tag other regional polymorphic
sites.
Conclusion
Our results indicate a protective effect of the OPG CGA
haplotype on CV risk, mainly due to a protective effect against
cerebrovascular events in anti-CCP negative RA patients.
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